OphthaFund
Dr. Magrath, a distinguished board-certified ophthalmologist and fellowship-trained ocular oncologist, is a leading figure in early-stage innovation and development in ophthalmology. Armed with a solid medical education, he furthered his qualifications with a Master of Applied Economics from Johns Hopkins and an MBA from the Citadel.
Dr. Magrath’s diverse career began as an equity analyst before transitioning into pharmaceutical development at Hovione. Notably, he assumed the role of CEO at Lexitas Pharma Services, a prominent contract research organization specializing in groundbreaking ophthalmic pharmaceuticals and medical devices.
Currently, Dr. Magrath holds a key position at Ocuphire Pharmaceuticals, a NASDAQ-traded company at the forefront of ophthalmic pharmaceuticals. In his role, he contributes to the development of an oral treatment for diabetic eye disease, showcasing his commitment to advancing medical solutions in the field.
OphthaFund
1 followers
We are early stage investors focused on the future of ophthalmology & life sciences. Working collaboratively with investors, OpthaFund selects the top companies in the industry in order to support and guide strategic investments. With a diversified investment portfolio, OphthaFund has already led numerous successful investments through funding rounds for innovators within the Ophthalmology industry.